Anebulo Pharmaceuticals Inc Stock Price, News & Analysis

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its financial results for Q1 fiscal 2022, highlighting key business developments. The company obtained a U.S. patent for ANEB-001, which is set to treat acute cannabinoid overdose. Manufacturing of ANEB-001 capsules is complete for the upcoming Phase 2 clinical trial. The company has formed a Scientific Advisory Board to guide its clinical programs. Operating expenses surged to $1.55 million, and the net loss was $1.55 million or $(0.07) per share. As of September 30, 2021, cash reserves stood at approximately $19.2 million.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 11,141,404, titled 'Formulations And Methods For Treating Acute Cannabinoid Overdose'. This patent covers ANEB-001, an investigational drug designed to treat acute cannabinoid overdose, with protection extending to 2040. CEO Daniel Schneeberger highlighted the urgent need for such treatments and confirmed a Phase 2 clinical study set for Q4 2023, with topline results expected in H1 2024.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its participation in the Benzinga Cannabis Capital Conference on October 14-15, 2021, in New York City. The management will present on October 15 at 3:25 p.m. Eastern Time and will engage in one-on-one meetings with investors throughout the event. Anebulo is focused on developing innovative treatments for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, demonstrating positive results in clinical trials. Investors can register for the event here.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its financial results for the fiscal year ending June 30, 2021. The company reported a net loss of $30.25 million, or $(2.83) per share, compared to a net loss of $174,637, or $(0.01) per share, in the previous year. Key highlights include the manufacturing of ANEB-001 capsules for a Phase 2 clinical trial, formation of a Scientific Advisory Board, and successful IPO raising $21.5 million. Management expects to initiate the Phase 2 trial for acute cannabinoid intoxication in Q4 2021, with topline results expected in H1 2022.

Anebulo Pharmaceuticals (ANEB) announced the successful completion of manufacturing its lead drug, ANEB-001, for an upcoming Phase 2 clinical trial targeting acute cannabinoid intoxication. The capsules, available in 10mg and 50mg, comply with Good Manufacturing Practices. CEO Daniel Schneeberger highlighted the significance of ANEB-001 in addressing a growing issue, with over 1.7 million cannabinoid-related emergency visits in 2018, increasing by 15% annually. The Phase 2 study is set to commence ahead of schedule, with initial results expected in the first half of next year.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company, announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present and hold one-on-one meetings with investors. A recorded presentation will be available on-demand starting September 13 on Anebulo’s website. Anebulo focuses on developing solutions for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, showing promising results in clinical trials.

Anebulo Pharmaceuticals (Nasdaq: ANEB) announced the formation of a Scientific Advisory Board (SAB) to enhance its clinical programs, co-chaired by experts Andrew Monte, M.D., Ph.D., and Arjun Chanmugam, M.D. The SAB will focus on advancing ANEB-001, aimed at treating acute cannabis intoxication, with a Phase 2 study expected to start in Q4 2021. The rise in cannabis-related emergency visits underscores the need for effective treatments. Anebulo's lead candidate is positioned uniquely in a growing market, with no direct competitors currently in advanced development.

Anebulo Pharmaceuticals reported significant developments and financial results for Q3 FY2021. The company successfully completed an IPO, selling 3,078,224 shares at $7.00, raising approximately $20.2 million. This funding supports ongoing operations and clinical trials for ANEB-001, aimed at treating cannabinoid intoxication, with a Phase 2 trial set to start in Q4 2021. Financially, the company incurred a net loss of $555,832, or $0.04 per share, with cash reserves at $3.3 million as of March 31, 2021. Anebulo expects the IPO proceeds to cover operations through December 2022.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) has announced its initial public offering (IPO) pricing of 3 million shares at $7.00 each, aiming for gross proceeds of approximately $21 million before costs. The offering includes a 30-day option for the underwriter to purchase an additional 450,000 shares. Trading is set to begin on Nasdaq on May 7, 2021, with the offering closing around May 11, 2021. Anebulo focuses on solutions for cannabinoid overdose and addiction, with its lead product, ANEB-001, designed to reverse overdose effects within one hour.